Agenus Inc. (AGEN) Dividend History

Agenus Inc. (AGEN) is a biotechnology company focused on the development of immunotherapies for cancer and infectious diseases. Founded in 1994, the company specializes in the research and development of innovative vaccine adjuvants and immune checkpoint modulators aimed at enhancing the body's immune response. Agenus's portfolio includes a range of monoclonal antibodies, vaccines, and other immunotherapeutic products targeting unmet medical needs.

3 Forbes Road, Lexington, MA, 02421
Phone: 781-674-4410
Website: https://www.agenusbio.com

Dividend History

Agenus Inc. currently does not pay dividends

Company News

  • Neoantigen Cancer Vaccines Industry Analysis Report 2025 with Tariff-Adjusted Forecasts and Analytics to 2030

    The global market for Neoantigen Cancer Vaccines is expected to grow significantly, driven by advancements in precision oncology, next-generation sequencing, and bioinformatics. Key players in this burgeoning market include Agenus Inc., BioNTech SE, and Candel Therapeutics.

    GlobeNewswire Inc.
  • Agenus (AGEN) Q3 2024 Earnings Call Transcript

    Agenus, a biotech company, reported its Q3 2024 earnings. The company's lead drug candidate, BOT/BAL, is showing promising results in treating various cancers, including microsatellite stable colorectal cancer. However, Agenus is facing financial challenges and is exploring strategic transactions and asset monetization to support the development of BOT/BAL.

    The Motley Fool
  • Agenus Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - AGEN

    Agenus Inc. (AGEN) is being sued for securities law violations related to the effectiveness of its immuno-oncology products botensilimab and balstilimab. The Gross Law Firm is encouraging investors who purchased AGEN shares during the class period to contact them regarding potential lead plaintiff appointment.

    Benzinga
  • LGND reaches 52-week high, hitting $103.295 - Investing.com

    Ligand Pharmaceuticals (LGND) has reached a new 52-week high of $103.295, reflecting the company's strong financial performance and growth potential. The company has made several strategic moves, including acquiring APEIRON Biologics and expanding its credit facility, which have contributed to its positive market performance.

    Investing.com
    Featured Companies: LGND
  • Agenus (AGEN) Tanks on Colorectal Cancer Study Interim Data - Zacks Investment Research

    Agenus Inc. (AGEN) shares plunged 58.8% after the FDA discouraged the accelerated approval pathway for the company's immunotherapy combination botensilimab (BOT) and balstilimab (BAL) in relapsed/refractory microsatellite stable colorectal cancer. The FDA cited concerns that the observed objective response rate might not translate to a survival benefit.

    Zacks Investment Research
    Featured Companies: ADPT ANIP RAPT
Page data last updated 07/23/2025 04:03:42 UTC